Shirey Jana K, Brady Ashley E, Jones Paulianda J, Davis Albert A, Bridges Thomas M, Kennedy J Phillip, Jadhav Satyawan B, Menon Usha N, Xiang Zixiu, Watson Mona L, Christian Edward P, Doherty James J, Quirk Michael C, Snyder Dean H, Lah James J, Levey Allan I, Nicolle Michelle M, Lindsley Craig W, Conn P Jeffrey
Department of Pharmacology, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee 37232-6600, USA.
J Neurosci. 2009 Nov 11;29(45):14271-86. doi: 10.1523/JNEUROSCI.3930-09.2009.
M(1) muscarinic acetylcholine receptors (mAChRs) may represent a viable target for treatment of disorders involving impaired cognitive function. However, a major limitation to testing this hypothesis has been a lack of highly selective ligands for individual mAChR subtypes. We now report the rigorous molecular characterization of a novel compound, benzylquinolone carboxylic acid (BQCA), which acts as a potent, highly selective positive allosteric modulator (PAM) of the rat M(1) receptor. This compound does not directly activate the receptor, but acts at an allosteric site to increase functional responses to orthosteric agonists. Radioligand binding studies revealed that BQCA increases M(1) receptor affinity for acetylcholine. We found that activation of the M(1) receptor by BQCA induces a robust inward current and increases spontaneous EPSCs in medial prefrontal cortex (mPFC) pyramidal cells, effects which are absent in acute slices from M(1) receptor knock-out mice. Furthermore, to determine the effect of BQCA on intact and functioning brain circuits, multiple single-unit recordings were obtained from the mPFC of rats that showed BQCA increases firing of mPFC pyramidal cells in vivo. BQCA also restored discrimination reversal learning in a transgenic mouse model of Alzheimer's disease and was found to regulate non-amyloidogenic APP processing in vitro, suggesting that M(1) receptor PAMs have the potential to provide both symptomatic and disease modifying effects in Alzheimer's disease patients. Together, these studies provide compelling evidence that M(1) receptor activation induces a dramatic excitation of PFC neurons and suggest that selectively activating the M(1) mAChR subtype may ameliorate impairments in cognitive function.
M(1)型毒蕈碱型乙酰胆碱受体(mAChRs)可能是治疗认知功能受损相关疾病的一个可行靶点。然而,检验这一假设的一个主要限制是缺乏针对单个mAChR亚型的高选择性配体。我们现在报告一种新型化合物苄基喹诺酮羧酸(BQCA)的严格分子特征,它是大鼠M(1)受体的一种强效、高选择性正变构调节剂(PAM)。该化合物不直接激活受体,而是作用于变构位点以增强对正构激动剂的功能反应。放射性配体结合研究表明,BQCA增加了M(1)受体对乙酰胆碱的亲和力。我们发现,BQCA激活M(1)受体可诱导强大的内向电流,并增加内侧前额叶皮质(mPFC)锥体细胞中的自发性兴奋性突触后电流(EPSCs),而在M(1)受体基因敲除小鼠的急性脑片中则没有这些效应。此外,为了确定BQCA对完整且功能正常的脑回路的影响,我们从大鼠的mPFC获得了多个单单位记录,结果显示BQCA在体内增加了mPFC锥体细胞的放电。BQCA还恢复了阿尔茨海默病转基因小鼠模型中的辨别逆转学习能力,并且在体外发现它可调节非淀粉样前体蛋白(APP)的加工,这表明M(1)受体PAM有潜力在阿尔茨海默病患者中提供症状缓解和疾病修饰作用。总之,这些研究提供了令人信服的证据,表明M(1)受体激活可诱导PFC神经元的显著兴奋,并表明选择性激活M(1) mAChR亚型可能改善认知功能障碍。